Novel use of combined 5-ht1a agonists and selective serotonin reuptake inhibitors
CA 2429216 C · Owner: Merck Patent Gesellschaft Mit Beschraenkter Haftung · Inventors: Bartoszyk, Gerd; Sedman, Ewen
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to the use of compounds being combined selective serotonin (5-HT) reuptake inhibitors (SSRIs) and 5-HT1A receptor agonists in , particular of 1-4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoyl-benzofuran-5-yl)piperazine or a physiologically acceptable salt thereof or 3-{4-4-(4-cyanophenyl)-piperazin-1-yl-butyl}-1H-indole-5-carbonitrile or a physiologically acceptable salt thereof, for the manufacture of a medicament for the treatment of chronic pain disorders or in treating other conditions where there is hypersensitization to painful signals, hyperalgesia allodynia, enhanced pain , perception, and enhanced memory of pain as well as for the treatment of , irritable …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 2, 2001 and granted August 7, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended November 2, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 2, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.